Phase 4 N=97 Randomized Triple-blind Treatment

Steroids After Laser Trabeculoplasty for Glaucoma

Glaucoma

Bottom Line

View on ClinicalTrials.gov: NCT00981435 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcome: Primary: Intraocular Pressure (IOP) Change — -3.0; -6.2; -5.2 mmHg

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Prednisolone 1% (Drug); Ketorolac (Drug); Artificial Tears (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Stanford University
Primary completion: Sep 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP) Change	-3.0; -6.2; -5.2	—
SECONDARY Intraocular Inflammation	0; 0; 0	—

Summary

The purpose of this study is to determine whether the choice of post-operative eye drop administered after selective laser trabeculoplasty (SLT) for glaucoma affects the efficacy in lowering intraocular pressure (IOP).

Eligibility Criteria

Inclusion Criteria

clinical diagnosis of glaucoma
clinician has determined that SLT laser is indicated
IOP currently >18 and was ever >21 in the past (e.g. prior to treatment)

Exclusion Criteria

prior history of uveitis
prior glaucoma surgery including glaucoma laser surgery
pregnant or 3 months post-partum

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00981435). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.